1. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
- Author
-
Franak Batliwalla, George Karypis, Timothy W. Behrens, Ward A. Ortmann, Katherine B. Shark, Emily C. Baechler, Patrick M. Gaffney, Peter K. Gregersen, Karl J. Espe, William J. Grande, Vivek Kapur, and Karis M. Hughes
- Subjects
Down-Regulation ,Biology ,Peripheral blood mononuclear cell ,Interferon ,Gene expression ,medicine ,Humans ,Lupus Erythematosus, Systemic ,skin and connective tissue diseases ,Oligonucleotide Array Sequence Analysis ,Autoimmune disease ,Regulation of gene expression ,Lupus Vulgaris ,Multidisciplinary ,Systemic lupus erythematosus ,Biological Sciences ,Flow Cytometry ,medicine.disease ,Up-Regulation ,Gene expression profiling ,Gene Expression Regulation ,Immunology ,Leukocytes, Mononuclear ,Interferons ,IRF5 ,medicine.drug - Abstract
Systemic lupus erythematosus (SLE) is a complex, inflammatory autoimmune disease that affects multiple organ systems. We used global gene expression profiling of peripheral blood mononuclear cells to identify distinct patterns of gene expression that distinguish most SLE patients from healthy controls. Strikingly, about half of the patients studied showed dysregulated expression of genes in the IFN pathway. Furthermore, this IFN gene expression “signature” served as a marker for more severe disease involving the kidneys, hematopoetic cells, and/or the central nervous system. These results provide insights into the genetic pathways underlying SLE, and identify a subgroup of patients who may benefit from therapies targeting the IFN pathway.
- Published
- 2003
- Full Text
- View/download PDF